JP2023539754A5 - - Google Patents
Info
- Publication number
- JP2023539754A5 JP2023539754A5 JP2023513976A JP2023513976A JP2023539754A5 JP 2023539754 A5 JP2023539754 A5 JP 2023539754A5 JP 2023513976 A JP2023513976 A JP 2023513976A JP 2023513976 A JP2023513976 A JP 2023513976A JP 2023539754 A5 JP2023539754 A5 JP 2023539754A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- tautomer
- stereoisomer
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073835P | 2020-09-02 | 2020-09-02 | |
| US63/073,835 | 2020-09-02 | ||
| PCT/US2021/048600 WO2022051326A1 (en) | 2020-09-02 | 2021-09-01 | Lzk‑targeting degraders and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539754A JP2023539754A (ja) | 2023-09-19 |
| JP2023539754A5 true JP2023539754A5 (enExample) | 2024-09-05 |
Family
ID=78087503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513976A Pending JP2023539754A (ja) | 2020-09-02 | 2021-09-01 | Ｌｚｋ標的化分解剤および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240190838A1 (enExample) |
| EP (1) | EP4208455A1 (enExample) |
| JP (1) | JP2023539754A (enExample) |
| AU (1) | AU2021336300A1 (enExample) |
| CA (1) | CA3193736A1 (enExample) |
| WO (1) | WO2022051326A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025188848A1 (en) * | 2024-03-06 | 2025-09-12 | Uereka Biosciences, Inc. | Lzk inhibitors |
| CN118652241A (zh) * | 2024-05-29 | 2024-09-17 | 浙江工业大学 | mTOR蛋白靶向降解嵌合体及其制备方法与应用 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2018044808A1 (en) | 2016-08-29 | 2018-03-08 | Board Of Regents, University Of Texas System | Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease |
| KR20190087622A (ko) * | 2016-12-08 | 2019-07-24 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제 |
| US10806737B2 (en) * | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| WO2019195609A2 (en) * | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US11560366B2 (en) * | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| WO2021141662A1 (en) * | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
-
2021
- 2021-09-01 CA CA3193736A patent/CA3193736A1/en active Pending
- 2021-09-01 WO PCT/US2021/048600 patent/WO2022051326A1/en not_active Ceased
- 2021-09-01 JP JP2023513976A patent/JP2023539754A/ja active Pending
- 2021-09-01 AU AU2021336300A patent/AU2021336300A1/en active Pending
- 2021-09-01 EP EP21790644.5A patent/EP4208455A1/en active Pending
-
2023
- 2023-03-01 US US18/176,849 patent/US20240190838A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539754A5 (enExample) | ||
| JP6784348B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| JP2011509309A5 (enExample) | ||
| US7217701B2 (en) | Intracellular calcium concentration increase inhibitors | |
| JP6078639B2 (ja) | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 | |
| TWI290552B (en) | Indole derivatives or benzimidazole derivatives for modulating IkB kinase | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| US8501793B2 (en) | Blood flow promoters for cauda equina tissues | |
| JP7475062B2 (ja) | ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法 | |
| TW200410688A (en) | Therapeutics for diseases from vasoconstriction or vasodilatation | |
| JP2024533121A5 (enExample) | ||
| US20050256160A1 (en) | Beta-alanine derivatives and the use thereof | |
| CN103664897A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| US6900207B2 (en) | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | |
| TW202003487A (zh) | 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法 | |
| JP2022119852A5 (enExample) | ||
| CN114008028A (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| US20070232586A1 (en) | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | |
| US6924295B2 (en) | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | |
| JP2013544794A5 (enExample) | ||
| CN101781268B (zh) | 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途 | |
| KR20200123184A (ko) | 증식이상 장애를 치료하기 위한 물질 및 방법 | |
| TW202132285A (zh) | 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法 | |
| JP2022521474A5 (enExample) |